Loading...

Robert H Weiss

TitleProfessor
InstitutionUniversity of California Davis
DepartmentNephrology
Address6300 GBSF
CA 95616
Phone530-752-4010
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    A Metabolomic Approach to Discovering Markers for ADPKD Progression
    NIH/NIDDK R01DK107416Aug 25, 2016 - May 31, 2019
    Role: Principal Investigator
    The addition of fish oil to sorafenib may prevent kidney cancer metastasis
    NIH/NCI R03CA181837Jan 1, 2014 - Dec 31, 2015
    Role: Principal Investigator
    A Metabolomic Approach to Discovering Biomarkers for ADPKD
    NIH/NIDDK R01DK082690Aug 17, 2009 - Jun 30, 2013
    Role: Principal Investigator
    Metabolomic discovery and validation of urinary biomarkers for kidney cancer
    NIH/NCI R01CA135401Mar 23, 2009 - Jan 31, 2015
    Role: Principal Investigator
    Cyclin Kinase Inhibitors as Molecular Targets for Cancer
    NIH/NCI R21CA091259Apr 1, 2002 - Mar 31, 2004
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Weiss RH. Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol. 2018 Mar; 38(2):175-182. PMID: 29602399.
      View in: PubMed
    2. Hu SL, Weiss RH. The role of nephrologists in the management of small renal masses. Nat Rev Nephrol. 2018 Apr; 14(4):211-212. PMID: 29398708.
      View in: PubMed
    3. Hoffman MD, Weiss RH. The Presented Evidence to Support Symptomatic Hypovolemic-Associated EAH Is Not Convincing. Curr Sports Med Rep. 2017 Nov/Dec; 16(6):464-466. PMID: 29135648.
      View in: PubMed
    4. Abu Aboud O, Habib SL, Trott J, Stewart B, Liang S, Chaudhari AJ, Sutcliffe J, Weiss RH. Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging. Cancer Res. 2017 12 01; 77(23):6746-6758. PMID: 29021138.
      View in: PubMed
    5. Hwang VJ, Zhou X, Chen X, Trott J, Abu Aboud O, Shim K, Dionne LK, Chmiel KJ, Senapedis W, Baloglu E, Mahjoub MR, Li X, Weiss RH. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease. Kidney Int. 2017 10; 92(4):922-933. PMID: 28545714.
      View in: PubMed
    6. Wettersten HI, Aboud OA, Lara PN, Weiss RH. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017 07; 13(7):410-419. PMID: 28480903.
      View in: PubMed
    7. Taylor SL, Ruhaak LR, Kelly K, Weiss RH, Kim K. Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices. Brief Bioinform. 2017 03 01; 18(2):312-320. PMID: 26896791.
      View in: PubMed
    8. Chen CH, Weiss RH. GHetting to know ADPKD proliferative signaling, STAT. Kidney Int. 2017 03; 91(3):524-526. PMID: 28202165.
      View in: PubMed
    9. Trott JF, Kim J, Abu Aboud O, Wettersten H, Stewart B, Berryhill G, Uzal F, Hovey RC, Chen CH, Anderson K, Graef A, Sarver AL, Modiano JF, Weiss RH. Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. Oncotarget. 2016 10 11; 7(41):66540-66557. PMID: 27572319.
      View in: PubMed
    10. Hwang VJ, Weiss RH. Metabolomic profiling for early cancer detection: current status and future prospects. Expert Opin Drug Metab Toxicol. 2016 Sep 23; 1-3. PMID: 27642860.
      View in: PubMed
    11. Taylor SL, Ruhaak LR, Weiss RH, Kelly K, Kim K. Multivariate two-part statistics for analysis of correlated mass spectrometry data from multiple biological specimens. Bioinformatics. 2017 01 01; 33(1):17-25. PMID: 27592710.
      View in: PubMed
    12. Hoffman MD, Weiss RH. Does Acute Kidney Injury From an Ultramarathon Increase the Risk for Greater Subsequent Injury? Clin J Sport Med. 2016 Sep; 26(5):417-22. PMID: 26657822.
      View in: PubMed
    13. Abu Aboud O, Chen CH, Senapedis W, Baloglu E, Argueta C, Weiss RH. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth. Mol Cancer Ther. 2016 09; 15(9):2119-29. PMID: 27390344; PMCID: PMC5010932 [Available on 09/01/17].
    14. Kim J, Stewart B, Weiss RH. Extraction and Quantification of Tryptophan and Kynurenine from Cultured Cells and Media Using a High Performance Liquid Chromatography (HPLC) System Equipped with an Ultra-Sensitive Diode Array Detector. Bio Protoc. 2016 Apr 05; 6(7). PMID: 27213172.
      View in: PubMed
    15. Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH. Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy. Mol Cancer Ther. 2016 05; 15(5):890-8. PMID: 26921392; PMCID: PMC4873345 [Available on 05/01/17].
    16. Elahi S, Weiss RH, Merani S. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS. 2016 Jan; 30(2):171-83. PMID: 26645604.
      View in: PubMed
    17. Hwang VJ, Kim J, Rand A, Yang C, Sturdivant S, Hammock B, Bell PD, Guay-Woodford LM, Weiss RH. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. Am J Physiol Renal Physiol. 2015 Sep 15; 309(6):F492-8. PMID: 26155843; PMCID: PMC4572393.
    18. Weiss RH. Cancers Best Paper Award 2015. Cancers (Basel). 2015 May 29; 7(2):963-5. PMID: 26791307; PMCID: PMC4491693.
    19. Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, Trott JF, Aboud OA, Stirdivant S, Neri B, Wolfert R, Stewart B, Perego R, Hsieh JJ, Weiss RH. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer Res. 2015 Jun 15; 75(12):2541-52. PMID: 25952651; PMCID: PMC4470795.
    20. Abu Aboud O, Donohoe D, Bultman S, Fitch M, Riiff T, Hellerstein M, Weiss RH. PPARa inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. Am J Physiol Cell Physiol. 2015 Jun 01; 308(11):C890-8. PMID: 25810260; PMCID: PMC4451352.
    21. Wettersten HI, Landesman Y, Friedlander S, Shacham S, Kauffman M, Weiss RH. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. PLoS One. 2014; 9(12):e113867. PMID: 25461627; PMCID: PMC4252068.
    22. Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD. Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol. 2015 Jan; 75(1):161-71. PMID: 25413440; PMCID: PMC4400119.
    23. Han J, Tan M, Sudheendra L, Weiss RH, Kennedy IM. On-chip detection of a single nucleotide polymorphism without polymerase amplification. Nano Res. 2014 Sep 01; 7(9):1302-1310. PMID: 25580203.
      View in: PubMed
    24. Zhang G, Panigrahy D, Hwang SH, Yang J, Mahakian LM, Wettersten HI, Liu JY, Wang Y, Ingham ES, Tam S, Kieran MW, Weiss RH, Ferrara KW, Hammock BD. Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11127-32. PMID: 25024195; PMCID: PMC4121808.
    25. Hoffman MD, Weiss RH. Symptomatic hypotonic hyponatremia presenting at high altitude. Wilderness Environ Med. 2014 Sep; 25(3):362-3. PMID: 24768570.
      View in: PubMed
    26. Wecksler AT, Hwang SH, Wettersten HI, Gilda JE, Patton A, Leon LJ, Carraway KL, Gomes AV, Baar K, Weiss RH, Hammock BD. Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer Drugs. 2014 Apr; 25(4):433-46. PMID: 24525589; PMCID: PMC3947856.
    27. Kim K, Mall C, Taylor SL, Hitchcock S, Zhang C, Wettersten HI, Jones AD, Chapman A, Weiss RH. Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment. PLoS One. 2014; 9(1):e86223. PMID: 24475090; PMCID: PMC3901684.
    28. Wettersten HI, Ganti S, Weiss RH. Metabolomic profiling of tumor-bearing mice. Methods Enzymol. 2014; 543:275-96. PMID: 24924138.
      View in: PubMed
    29. Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD. Anti-inflammatory effects of ?-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol. 2013 Sep; 62(3):285-97. PMID: 23676336; PMCID: PMC3773051.
    30. Abu Aboud O, Wettersten HI, Weiss RH. Inhibition of PPARa induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One. 2013; 8(8):e71115. PMID: 23951092; PMCID: PMC3737191.
    31. Liu R, Wettersten HI, Park SH, Weiss RH. Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer. Future Med Chem. 2013 Jun; 5(9):991-4. PMID: 23734682; PMCID: PMC4573579.
    32. Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, Wettersten HI, Ulu A, Hu X, Tam S, Hwang SH, Ingham ES, Kieran MW, Weiss RH, Ferrara KW, Hammock BD. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A. 2013 Apr 16; 110(16):6530-5. PMID: 23553837; PMCID: PMC3631682.
    33. Wettersten HI, Weiss RH. Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol. 2013 Jun; 10(6):336-44. PMID: 23545813.
      View in: PubMed
    34. Martin KS, Soldi C, Candee KN, Wettersten HI, Weiss RH, Shaw JT. From bead to flask: Synthesis of a complex ß-amido-amide for probe-development studies. Beilstein J Org Chem. 2013; 9:260-4. PMID: 23400429; PMCID: PMC3566855.
    35. Wettersten HI, Hee Hwang S, Li C, Shiu EY, Wecksler AT, Hammock BD, Weiss RH. A novel p21 attenuator which is structurally related to sorafenib. Cancer Biol Ther. 2013 Mar; 14(3):278-85. PMID: 23298903; PMCID: PMC3595311.
    36. Wettersten HI, Weiss RH. Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets. Organogenesis. 2013 Jan-Mar; 9(1):11-8. PMID: 23538740; PMCID: PMC3674034.
    37. Aboud OA, Weiss RH. New opportunities from the cancer metabolome. Clin Chem. 2013 Jan; 59(1):138-46. PMID: 23150057.
      View in: PubMed
    38. Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP, Weiss RH. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol. 2013 Jun; 189(6):2317-26. PMID: 23079374.
      View in: PubMed
    39. Ganti S, Taylor SL, Abu Aboud O, Yang J, Evans C, Osier MV, Alexander DC, Kim K, Weiss RH. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res. 2012 Jul 15; 72(14):3471-9. PMID: 22628425; PMCID: PMC3399039.
    40. Inoue H, Hwang SH, Wecksler AT, Hammock BD, Weiss RH. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther. 2011 Nov 01; 12(9):827-36. PMID: 21878748; PMCID: PMC3225758.
    41. Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol. 2011 Oct 25; 8(1):22-33. PMID: 22025087.
      View in: PubMed
    42. Ganti S, Taylor SL, Kim K, Hoppel CL, Guo L, Yang J, Evans C, Weiss RH. Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer. 2012 Jun 15; 130(12):2791-800. PMID: 21732340; PMCID: PMC3258465.
    43. Ganti S, Weiss RH. Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol. 2011 Sep-Oct; 29(5):551-7. PMID: 21930086; PMCID: PMC3177099.
    44. Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS. 2011 May; 15(5):293-303. PMID: 21348635; PMCID: PMC3125558.
    45. Ishimaru T, Lau J, Jackson AL, Modiano JF, Weiss RH. Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma. J Urol. 2010 Nov; 184(5):2143-9. PMID: 20850841.
      View in: PubMed
    46. Taylor SL, Ganti S, Bukanov NO, Chapman A, Fiehn O, Osier M, Kim K, Weiss RH. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol. 2010 Apr; 298(4):F909-22. PMID: 20130118; PMCID: PMC2853321.
    47. Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD, Weiss RH. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther. 2009 Aug; 8(8):2193-203. PMID: 19671760; PMCID: PMC2728155.
    48. Perroud B, Ishimaru T, Borowsky AD, Weiss RH. Grade-dependent proteomics characterization of kidney cancer. Mol Cell Proteomics. 2009 May; 8(5):971-85. PMID: 19164279; PMCID: PMC2689781.
    49. Park SH, Wang X, Liu R, Lam KS, Weiss RH. High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. Cancer Biol Ther. 2008 Dec; 7(12):2015-22. PMID: 18981726.
      View in: PubMed
    50. Park JY, Park SH, Weiss RH. Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease. Am J Nephrol. 2009; 29(6):509-15. PMID: 19066425; PMCID: PMC2818470.
    51. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics. 2009 Mar; 8(3):558-70. PMID: 19008263; PMCID: PMC2649817.
    52. Park SH, Park JY, Weiss RH. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J Urol. 2008 Jul; 180(1):352-60. PMID: 18499163; PMCID: PMC2705194.
    53. Son A, Dhirapong A, Dosev DK, Kennedy IM, Weiss RH, Hristova KR. Rapid and quantitative DNA analysis of genetic mutations for polycystic kidney disease (PKD) using magnetic/luminescent nanoparticles. Anal Bioanal Chem. 2008 Apr; 390(7):1829-35. PMID: 18256809.
      View in: PubMed
    54. Park JY, Schutzer WE, Lindsley JN, Bagby SP, Oyama TT, Anderson S, Weiss RH. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol. 2007 Aug 22; 8:12. PMID: 17714589; PMCID: PMC2045080.
    55. Park JY, Lin PY, Weiss RH. Targeting the PI3K-Akt pathway in kidney cancer. Expert Rev Anticancer Ther. 2007 Jun; 7(6):863-70. PMID: 17555396.
      View in: PubMed
    56. Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modiano JF, Weiss RH. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer. 2007 Feb 14; 6:16. PMID: 17300726; PMCID: PMC1803787.
    57. Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem. 2007 Apr 15; 363(2):185-95. PMID: 17316536.
      View in: PubMed
    58. Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, Figlin RA, Pantuck AD. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol. 2007 Jan; 177(1):63-8; discussion 68-9. PMID: 17162001.
      View in: PubMed
    59. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kültz D, Weiss RH. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006 Nov 24; 5:64. PMID: 17123452; PMCID: PMC1665458.
    60. Weiss RH, Lin PY. Kidney cancer: identification of novel targets for therapy. Kidney Int. 2006 Jan; 69(2):224-32. PMID: 16408110.
      View in: PubMed
    61. Davis BB, Morisseau C, Newman JW, Pedersen TL, Hammock BD, Weiss RH. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J Pharmacol Exp Ther. 2006 Feb; 316(2):815-21. PMID: 16221742.
      View in: PubMed
    62. Tang V, Dhirapong A, Yabes AP, Weiss RH. TNF-alpha-mediated apoptosis in vascular smooth muscle cells requires p73. Am J Physiol Cell Physiol. 2005 Jul; 289(1):C199-206. PMID: 15716325.
      View in: PubMed
    63. Fan YP, Weiss RH. Exogenous attenuation of p21(Waf1/Cip1) decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1. J Am Soc Nephrol. 2004 Mar; 15(3):575-84. PMID: 14978159.
      View in: PubMed
    64. Dong Y, Chi SL, Borowsky AD, Fan Y, Weiss RH. Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal. 2004 Feb; 16(2):263-9. PMID: 14636896.
      View in: PubMed
    65. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell. 2003 Dec; 4(6):425-9. PMID: 14706334.
      View in: PubMed
    66. Fan Y, Borowsky AD, Weiss RH. An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther. 2003 Aug; 2(8):773-82. PMID: 12939467.
      View in: PubMed
    67. Wong GA, Tang V, El-Sabeawy F, Weiss RH. BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1. Am J Physiol Endocrinol Metab. 2003 May; 284(5):E972-9. PMID: 12527559.
      View in: PubMed
    68. Weiss RH, Marshall D, Howard L, Corbacho AM, Cheung AT, Sawai ET. Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/Cip1). Cancer Lett. 2003 Jan 10; 189(1):39-48. PMID: 12445676.
      View in: PubMed
    69. Davis BB, Dong Y, Weiss RH. Overexpression of p73 causes apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2003 Jan; 284(1):C16-23. PMID: 12388104.
      View in: PubMed
    70. Weiss RH, Randour CJ. Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21(Waf1/Cip1). Atherosclerosis. 2002 Mar; 161(1):105-12. PMID: 11882322.
      View in: PubMed
    71. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, Weiss RH. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A. 2002 Feb 19; 99(4):2222-7. PMID: 11842228; PMCID: PMC122346.
    72. Weiss RH, Howard LL. p73 is a growth-regulated protein in vascular smooth muscle cells and is present at high levels in human atherosclerotic plaque. Cell Signal. 2001 Oct; 13(10):727-33. PMID: 11602183.
      View in: PubMed
    73. Weiss RH, Randour CJ. The permissive effect of p21(Waf1/Cip1) on DNA synthesis is dependent on cell type: effect is absent in p53-inactive cells. Cell Signal. 2000 Jun; 12(6):413-8. PMID: 10889470.
      View in: PubMed
    74. Weiss RH, Joo A, Randour C. p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem. 2000 Apr 07; 275(14):10285-90. PMID: 10744715.
      View in: PubMed
    75. Weiss RH, Ramirez A, Joo A. Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. J Am Soc Nephrol. 1999 Sep; 10(9):1880-90. PMID: 10477139.
      View in: PubMed
    76. Weiss RH. G protein-coupled receptor signalling in the kidney. Cell Signal. 1998 May; 10(5):313-20. PMID: 9692674.
      View in: PubMed